Analysis of Drug Resistance of Streptococcus agalactiae in Neonates
Objective To analyze the detection of Streptococcus agalactiae(Group B Streptococcus)and its drug resistance in neonates within a general hospital.This analysis aims to provide clinicians with valuable insights for treating neonatal Streptococcus agalactiae infections effectively.Methods Between January 2017 and December 2022,isolates of Streptococcus agalactiae were obtained from the hospital's neonatal unit.All strains underwent drug susceptibility testing using the BD PhoenixTM-100 fully automated microbiology analyzer or the paper diffusion method.Results Over the period of 2017 to 2022,the neonatal unit recorded a total of 16,772 hospitalizations,among which 243 strains of Streptococcus agalactiae were identified.Gastric fluid secretion specimens accounted for 76.54％(186 strains),followed by blood specimens at 20.99％(51 strains).The number of Streptococcus agalactiae infections was slightly higher in female neonates compared to males.Drug susceptibility testing revealed that strains showed no resistance to ampicillin,cefepime,linezolid,meropenem,penicillin,and vancomycin.However,erythromycin had a resistance rate of more than 57.1％over the six-year period;tetracycline had a resistance rate of more than 64.7％over the same period,totaling 73.8％;and levofloxacin had a six-year resistance rate ranging from 25.5％to 42.9％,with an overall resistance rate of 31.4％.Conclusion This work provides a critical basis for the prevention and management of Streptococcus agalactiae infections in neonates.It aims to assist pediatric clinicians in minimizing the risk of adverse outcomes in neonatal care.
NETL
NSTL
万方数据
